Vivos Therapeutics annual net debt
2019
2020
2021
2022
2023
2024
2025
Vivos Therapeutics Net Debt Growth & History (VVOS)
Vivos Therapeutics's net debt was $11.5M for fiscal 2025.
View full Vivos Therapeutics company overviewVivos Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.5M | $15.0M | — |
| 2024 | 2024-12-31 | −$3.5M | −$5.1M | — |
| 2023 | 2023-12-31 | $1.6M | $2.7M | — |
| 2022 | 2022-12-31 | −$1.1M | $20.9M | — |
| 2021 | 2021-12-31 | −$22.1M | −$5.1M | — |
| 2020 | 2020-12-31 | −$16.9M | −$20.2M | — |
| 2019 | 2019-12-31 | $3.2M | — | — |
Vivos Therapeutics quarterly net debt
Q4.19
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.7M | $3.6M | +49.48% |
| Q1 2026 | 2026-03-31 | $10.2M | $11.1M | — |
| Q4 2025 | 2025-12-31 | $11.5M | $15.0M | — |
| Q3 2025 | 2025-09-30 | $9.4M | $12.9M | — |
| Q2 2025 | 2025-06-30 | $7.2M | $11.1M | — |
| Q1 2025 | 2025-03-31 | −$943,000 | −$214,000 | — |
| Q4 2024 | 2024-12-31 | −$3.5M | −$5.1M | — |
| Q3 2024 | 2024-09-30 | −$3.5M | −$5.8M | — |
| Q2 2024 | 2024-06-30 | −$3.9M | −$3.4M | — |
| Q1 2024 | 2024-03-31 | −$729,000 | $4.0M | — |
| Q4 2023 | 2023-12-31 | $1.6M | $2.7M | — |
| Q3 2023 | 2023-09-30 | $2.3M | $6.2M | — |
| Q2 2023 | 2023-06-30 | −$531,000 | $9.2M | — |
| Q1 2023 | 2023-03-31 | −$4.7M | $10.9M | — |
| Q4 2022 | 2022-12-31 | −$1.1M | $20.9M | — |
| Q3 2022 | 2022-09-30 | −$3.9M | $23.4M | — |
| Q2 2022 | 2022-06-30 | −$9.8M | $23.2M | — |
| Q1 2022 | 2022-03-31 | −$15.6M | −$2.8M | — |
| Q4 2021 | 2021-12-31 | −$22.1M | −$5.1M | — |
| Q3 2021 | 2021-09-30 | −$27.3M | — | — |
| Q2 2021 | 2021-06-30 | −$32.9M | — | — |
| Q1 2021 | 2021-03-31 | −$12.8M | — | — |
| Q4 2020 | 2020-12-31 | −$16.9M | −$20.2M | — |
| Q4 2019 | 2019-12-31 | $3.2M | — | — |
Vivos Therapeutics net debt trends
Over the last five fiscal years, Vivos Therapeutics's net debt increased from −$16.9M to $11.5M, a change of $28.4M. The latest reported quarter, Q2 2026, shows $10.7M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vivos Therapeutics source filings ↗